[Effect of tranilast, an anti-allergic drug, on carrageenin-induced granulation and capillary permeability in rats].
We studied the effect of tranilast on the growth of carrageenin-induced granulation and the increase in capillary permeability induced by inflammatory agents in rats. In the carrageenin-induced granulation model, tranilast (50 or 100-200 mg/kg, p.o.) decreased significantly and dose-dependently the weight and the hydroxyproline content of the granulation tissue. Tranilast, however, showed no effect on the healing day of locally wounded dorsal skin of rats. Triamcinolone (10 mg/kg, p.o.) also showed an inhibitory effect on the carrageenin-induced granulation model. Tranilast (50-400 mg/kg, p.o.) dose-dependently inhibited the enhancement of capillary permeability induced by the Ca ionophore A23187, bradykinin and xanthine oxidase. Moreover, tranilast (30 and 300 microM) suppressed superoxide production induced by FMLP in human neutrophils, but did not act as a superoxide scavenger. Considering that hypertrophic scar and keloid are conditions characterized by abnormal cell proliferation and excessive collagen accumulation accompanied with itch and pain, these results suggest that tranilast is useful as a therapeutic drug for hypertrophic scars and keloids.
Suzawa
H
H
Medical information, Kissei Pharmaceutical Co., Ltd., Matsumoto, Japan.
Ichikawa
K
K
Kikuchi
S
S
Yamada
K
K
Tsuchiya
O
O
Hamano
S
S
Komatsu
H
H
Miyata
H
H
D000328:Adult; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects*; D002351:Carrageenan; D002921:Cicatrix / Q000188:drug therapy; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006097:Granulation Tissue / Q000187:drug effects*; D006634:Histamine H1 Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007627:Keloid / Q000188:drug therapy; D008297:Male; D009504:Neutrophils / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D013481:Superoxides / Q000378:metabolism; D062367:ortho-Aminobenzoates / Q000494:pharmacology* / Q000627:therapeutic use
D006634:Histamine H1 Antagonists; D062367:ortho-Aminobenzoates; D013481:Superoxides; D002351:Carrageenan; C012293:tranilast